

UNIVERSIDADE ESTADUAL DE CAMPINAS  
SISTEMA DE BIBLIOTECAS DA UNICAMP  
REPOSITÓRIO DA PRODUÇÃO CIENTÍFICA E INTELECTUAL DA UNICAMP

**Versão do arquivo anexado / Version of attached file:**

Versão do Editor / Published Version

**Mais informações no site da editora / Further information on publisher's website:**

<https://www.scielo.br/j/abo/a/Cv9RQXvsvWs5bSg9nz6Y6BP>

**DOI: 10.5935/0004-2749.20140061**

**Direitos autorais / Publisher's copyright statement:**

©2014 by Conselho Brasileiro de Oftalmologia. All rights reserved.

DIRETORIA DE TRATAMENTO DA INFORMAÇÃO

Cidade Universitária Zeferino Vaz Barão Geraldo

CEP 13083-970 – Campinas SP

Fone: (19) 3521-6493

<http://www.repositorio.unicamp.br>

# Applications of visual evoked potentials and Fourier-domain optical coherence tomography in Parkinson's disease: a controlled study

## Potenciais evocados visuais e tomografia de coerência óptica com domínio de Fourier na doença de Parkinson: um estudo controlado

LUCAS BARASNEVICIUS QUAGLIATO<sup>1</sup>, CAROLINA DOMINGUES<sup>1</sup>, ELIZABETH MARIA APARECIDA BARASNEVICIUS QUAGLIATO<sup>2</sup>, ELVIRA BARBOSA DE ABREU<sup>3</sup>, NEWTON KARA-JUNIOR<sup>4</sup>

### ABSTRACT

**Purpose:** The goal of this cross-sectional observational study was to quantify the pattern-shift visual evoked potentials (VEP) and the thickness as well as the volume of retinal layers using optical coherence tomography (OCT) across a cohort of Parkinson's disease (PD) patients and age-matched controls.

**Methods:** Forty-three PD patients and 38 controls were enrolled. All participants underwent a detailed neurological and ophthalmologic evaluation. Idiopathic PD cases were included. Cases with glaucoma or increased intra-ocular pressure were excluded. Patients were assessed by VEP and high-resolution Fourier-domain OCT, which quantified the inner and outer thicknesses of the retinal layers. VEP latencies and the thicknesses of the retinal layers were the main outcome measures.

**Results:** The mean age, with standard deviation (SD), of the PD patients and controls were 63.1 (7.5) and 62.4 (7.2) years, respectively. The patients were predominantly in the initial Hoehn-Yahr (HY) disease stages (34.8% in stage 1 or 1.5, and 55.8% in stage 2). The VEP latencies and the thicknesses as well as the volumes of the retinal inner and outer layers of the groups were similar. A negative correlation between the retinal thickness and the age was noted in both groups. The thickness of the retinal nerve fibre layer (RNFL) was 102.7 µm in PD patients vs. 104.2 µm in controls.

**Conclusions:** The thicknesses of retinal layers, VEP, and RNFL of PD patients were similar to those of the controls. Despite the use of a representative cohort of PD patients and high-resolution OCT in this study, further studies are required to establish the validity of using OCT and VEP measurements as the anatomic and functional biomarkers for the evaluation of retinal and visual pathways in PD patients.

**Keywords:** Evoked potentials, visual; Tomography, optical coherence/methods; Parkinson disease

### RESUMO

**Objetivo:** Este estudo observacional transversal controlado visou quantificar os potenciais evocados visuais com estímulo de padrões alternantes (PEV), a espessura e o volume das camadas retinianas com tomografia de coerência óptica (TCO) num grupo de pacientes com doença de Parkinson (DP).

**Métodos:** Quarenta e três pacientes com DP e 38 controles. Procedimentos: pacientes e controles foram submetidos a exames neurológico e oftalmológico detalhados, sendo incluídos pacientes com DP idiopática e excluídos casos com glaucoma ou aumento da pressão intraocular. Todos os participantes foram estudados com PEV e TCO de Fourier, sendo quantificadas as latências de P100, a espessura e o volume das camadas retinianas interna e externa.

**Resultados:** A média das idades e desvio-padrão dos pacientes com DP e controles foram respectivamente 63,1(7,5) e 62,4 (7,2) anos. Os pacientes com DP situaram-se predominantemente nos estágios iniciais de Hoehn-Yahr (34.8% no estágio 1 ou 1.5; 55.8% no estágio 2). Não foram observadas diferenças entre os dois grupos quanto às latências dos PEV, a espessura e o volume das camadas retinianas. Observamos uma correlação negativa entre a espessura das camadas retinianas e a idade em ambos os grupos. Não se observou diferença significativa quanto à espessura da camada retiniana das fibras do nervo óptico (CRFNO), que foi de 102,7 µm nos pacientes e 104,2 µm nos controles.

**Conclusões:** A espessura das camadas retinianas, os PEV e a espessura da CRFNO foi semelhante nos pacientes com DP e controles. Apesar desse grupo representativo de pacientes com DP e da alta resolução da TCO utilizada neste estudo, mais estudos são necessários para estabelecer o papel da TCO e dos PEV como biomarcadores anatômico e funcional na avaliação da retina e da via visual dos pacientes com DP.

**Descritores:** Potenciais evocados visuais; Tomografia de coerência óptica/métodos; Doença de Parkinson

### INTRODUCTION

Parkinson's Disease (PD) is the second most common neurodegenerative disease, affecting 1-2 % of the world's population above the age 65<sup>(1)</sup>. The non-motor symptoms (olfactory, autonomic, and visual) of PD have been described. Ophthalmological symptoms include blurred vision due to dry eye, and diplopia from convergence insufficiency. Additionally, it has been reported that PD patients

present abnormalities in pattern-shift visual evoked potentials (VEP), contrast sensitivity, and colour vision<sup>(3-5)</sup>. The human retina contains dopaminergic amacrine and interplexiform cells, which play a regulatory role. Dopaminergic D1 and D2 receptors are essentials for the receptive field organization of the ganglion cells<sup>(6-9)</sup>. Optical coherence tomography (OCT), a non-invasive optical interferometric method, generates cross-sectional retinal images *in vivo*. Earlier studies using

Submitted for publication: September 3, 2013

Accepted for publication: May 1, 2014

Study conducted at Dr. João Penido Burnier Ophthalmologic Foundation Campinas - SP

<sup>1</sup> Department of Ophthalmology, Universidade Estadual de Campinas, SP, Brazil.

<sup>2</sup> Department of Neurology, Universidade Estadual de Campinas, SP, Brazil.

<sup>3</sup> Dr. João Penido Burnier Ophthalmologic Foundation, Campinas, SP, Brazil.

<sup>4</sup> Department of Ophthalmology, Universidade de São Paulo, SP, Brazil.

**Funding:** No specific financial support was available for this study.

**Disclosure of potential conflicts of interest:** None of the authors have any potential conflicts of interest to disclose.

**Corresponding author:** Lucas Barasnevicus Quagliato. Rua Alfredo Calil, 187 - Campinas - SP - 13101-507 - Brazil - E-mail: lucasquagliato@yahoo.com.br

time-domain and spectral-domain OCT have found evidence for the retinal changes in PD patients. However, these findings have not been independently verified. Four separate studies have reported thinning of the inner retinal layer in PD patients<sup>(10-13)</sup>. Two of these studies found a significant thinning of the peripapillary retinal nerve fibre layer (RNFL) only in the inferior and temporal retinas of some PD patients<sup>(10,13)</sup>. An independent study found a reduction in the mean total thickness of the peripapillary RNFL and reduced macular volume in 17 PD patients<sup>(11)</sup>. Further, there was an inverse correlation between the macular thickness and the motor handicap. The objectives of this study were to define VEP and Fourier-domain high-resolution OCT images as functional and biological marker, respectively of PD. These tools allow the analysis of maculo-cortical pathway (via VEP) and enable retinal measurements (via OCT), and therefore, could address the retinal contribution to the visual dysfunction in PD.

## METHODS

### PATIENTS AND STUDY POPULATION

This cross-sectional observational study recruited 43 idiopathic PD patients and 38 age-matched controls from a specialised PD clinic. A neurologist (E.M.A.B.Q), who also performed the VEP measurements, made the diagnosis based on the UK Brain Bank criteria<sup>(14)</sup> and applied the United Parkinson Disease Scale (UPDRS). Patients were under dopaminergic medications at the time of the study. The Hoehn-Yahr (HY) stage was established in an *off* stage, without the effects of medication. All patients were between the HY stages 1 and 3 (mean 1.78). Exclusion criteria were the following: systemic co-morbidities such as neoplasia, diabetes, severe arterial hypertension, glaucoma or intraocular pressure greater than 20 mmHg, posterior-pole eye diseases such as macular degeneration or any optic neuropathy, or a best-corrected visual acuity worse than 20/30. The ophthalmologic evaluation and the OCT were performed at an *on* stage by one of three ophthalmologists involved in this study (L.B.Q., C.D., and E.B.A.) and comprised a visual acuity test (Snellen table), an Ishihara colors test, a biomicroscopy, and an intraocular pressure measurement using the Goldmann applanation tonometer. We examined 86 eyes of 43 PD patients and 76 eyes of 38 controls. All participants signed an informed consent form. The study was approved on 8/24/2010 by the ethical committee of the State University of Campinas (SP) and was conducted according to the Good Practice Guidelines (1977), the Helsinki Declaration (2000 version), and the Brazilian Clinical Study Guidelines.

### EQUIPMENT AND MEASURES

Neurophysiologic analysis: a Nihon-Kohden 4-channel device registered VEP using a full-field checkerboard pattern (black and white), applying a 2-Hz stimuli and a controlled background luminance. Responses to the stimuli with a visual angle of 30° were considered for statistical analysis. Electrodes were placed on the scalp according to the 10/20 International System. The electrode was placed 5 cm above theinion and the reference electrode was placed over the midline frontal region (FpZ). Eyes were stimulated individually. The average responses from two trials of 150 stimuli for each eye were superimposed using a 1-Hz-100-Hz filter. Latencies and amplitudes of N75, P100, and N135 were measured. However, only the P100 latencies were considered for statistical analysis.

Morphological analysis: a Fourier-domain OCT (RTVue; Optovue, Cal, USA), with an approximate resolution of 5 µm, was used for examining the retinal morphology. The OCT examined an area corresponding to the central and paracentral visual fields. The standard glaucoma protocol, consisting of optic nerve head map scans and macula map scans, was performed in both PD patients and controls. The protocol measured the mean inner (IRL), outer (ORL), and full retinal layer (FRL) thicknesses, the volume of the parafoveal (diameter=3.00 mm) and perifoveal (diameter 5.00 mm) regions, and the

RNFL average mean thickness over a diameter of 3.45 mm for both superior and inferior hemispheres. The IRL includes the nerve fibre layer, the ganglion cell layer, and the inner plexiform layer. The ORL includes the retinal layers starting from the inner nuclear layer up to and including the retinal pigment epithelium. The OCT instrument was equipped with an eye tracker that compensated for the eye movement. When motion or media artefacts were detected, the OCT measurements were repeated.

### STATISTICAL ANALYSIS

Statistical analysis was performed using the descriptive statistics and employed no parametric tests. The data have been presented as the mean values and standard deviation to enable comparisons with published results. The Chi-square and Fisher's exact tests (for values less than 5) were used to compare the categorical variables. The Mann-Whitney and Kruskal-Wallis tests were used for comparing the numeric variables between two or three groups. The Spearman rank coefficient (*r*) was used to analyze the relationships between the numerical variables. Correlation was considered strong if  $r \geq 0.70$ , moderate if  $0.70 > r > 0.50$ , weak if  $0.20 < r < 0.50$ , and no correlation if  $r \leq 0.20$ . The adopted significance level for the statistical tests was 5% ( $P < 0.05$ ).

## RESULTS

The age frequencies were similar in both groups-28 subjects between the ages of 50 and 59 years (13 controls and 15 PD), 37 subjects between the ages of 60 and 69 years (18 controls and 19 PD), and 16 subjects between the ages of 70 and 79 years (7 controls and 9 PD) ( $Q$ -square=0.11,  $P=0.946$ ). Thirteen PD patients (31.28%) and 8 control subjects (22.21%) included symptoms ( $P=0.365$ ) such as visual tiredness (10 patients), dry eye (5), and blurred vision (5). Similarly, the symptoms presented by the control subjects include tiredness (2), dry eye (2), and blurred vision (5). Basic demographic data are shown in table 1.

### CONTROL GROUP VS. PD GROUP: ISHIIHARA COLOR TEST

The scores of PD patients and control subjects were normal (91.89% and 97.37%, respectively;  $P=0.358$ ).

### CONTROL GROUP VS. PD GROUP: VISUAL EVOKED POTENTIALS

The mean (SD) P100 cortical latencies obtained after stimulating the right eye of controls and PD patients were 106.35(6.99) ms and 108.36(10.23) ms ( $P=0.365$ ), respectively. The mean cortical latencies for the left eye were 108.15(6.97) and 109.13(8.87) ms ( $P=0.728$ ), respectively. The average of the P100 latencies of the right and left eyes were 107.25(6.57) ms and 108.75(9.27) ms, respectively in controls and PD patients ( $P=0.516$ ). Thus, the cortical VEP responses (P100), with a visual angle of 30°, showed similar latencies in both patients and controls.

**Table 1. Basic demographic data**

	Controls n=38	PD n=43	P value
Age (years) (SD)	62.4 (7.2)	63.1 (7.55)	0.656
Gender (% male)	46.15	62.79	0.131
Race (% white)	97.37	93.20	0.700
PD duration (years) (SD)		6.98 (4.13)	
Normal Ishihara color test (%)	97.37	91.89	
Hohen-Yahr stages 1 and 1.5 (%)		34.88	0.358
Hohen-Yahr stage 2 (%)		55.81	
Hohen-Yahr stages 2.5 and 3 (%)		9.31	
UPDRS total (mean) (SD)		17.63 (8.99)	

UPDRS= united Parkinson disease rating scale; Statistical tests= Chi-squared and Fisher's exact test.

Within the control group, there was a positive correlation between the age, and the cortical VEP latencies of the right and left eyes ( $r=0.42543$  and  $0.43343$ , respectively;  $P=0.0108$  and  $0.0093$ , respectively), and between the age and the average of the latencies of the right and left eye ( $r=0.41969$ ,  $P=0.0121$ ). In the PD group, there was no correlation between the age and the VEP latencies of the right and left eyes ( $r=0.05669$  and  $0.10101$ ;  $P=0.7214$  and  $0.5245$ , respectively), and the average of the latencies of the right and left eyes ( $r=0.07507$ ;  $P=0.6366$ ). There was no correlation between the PD duration and the VEP latencies for the right eyes and left eyes ( $r=0.21453$  and  $r=0.07592$ ;  $P=0.1725$  and  $0.6328$ , respectively), as well as between the PD duration and the average of the VEP latencies of the right and left eyes ( $r=0.13992$ ,  $P=0.3768$ ). There was no correlation between the HY stage and the VEP latencies of the right and left eyes ( $r=0.06210$  and  $0.03200$ , respectively;  $P=0.6960$  and  $0.8405$ , respectively), and between the HY stage and the average of the VEP latencies of the right and left eyes ( $r=0.04989$ ,  $P=0.7537$ ). There was no correlation between the UPDRS total scores and the VEP latencies for the right and left eye ( $r=0.1482$  and  $0.20985$ , respectively;  $P=0.3635$  and  $0.1822$ , respectively), and between the UPDRS total scores and the average of the latencies of both eyes ( $r=0.21471$ ,  $P=0.1721$ ).

#### CONTROL GROUP VS. PD GROUP: OPTICAL COHERENCE TOMOGRAPHY

The mean (SD) interocular RNFL thickness was similar in controls [ $104.17$  ( $12.31$ )  $\mu\text{m}$ ] and PD patients [ $102.68$  ( $11.50$ )  $\mu\text{m}$ ] ( $P=0.169$ ). The inner, outer, and the total layer thicknesses as well as the volumes of the parafoveal and perifoveal regions of both eyes of the PD patients were similar to those of controls. The OCT results are summarised in tables 2 and 3.

#### CORRELATIONS IN PD GROUP

A negative correlation was found between the age of the PD patients and the retinal layer thickness as well as the volume. Increased age was associated with a thinner right eye inner perifoveal layer (Figure 1), lower right eye inner perifoveal layer volume ( $r=-0.41840$ ,  $P=0.0080$ ), and lower total right eye perifoveal layer thickness ( $r=-0.32039$ ,  $P=0.0468$ ).

**Table 2. RNFL thickness and macular parafoveal layer thickness and volume analysis**

	Control	PD	P value
RNFL thickness ( $\mu\text{m}$ ; SD)	n=38	n=43	
OD mean	105.85 (12.82)	103.09 (12.04)	0.098
OS mean	103.41 (11.58)	102.27 (12.19)	0.244
Mean macular thickness ( $\mu\text{m}$ ; SD)			
OD inner parafoveal layer	123.00 (10.98)	121.51 (11.03)	0.552
OS inner parafoveal layer	120.67 (16.16)	125.18 ( 9.88)	0.310
Mean inner interocular parafoveal	121.83 (11.40)	123.35 ( 9.42)	0.908
OD outer parafoveal layer	193.18 (45.16)	188.05 (12.27)	0.738
OS outer parafoveal layer	183.21 (16.07)	184.41 ( 7.56)	0.936
Mean outer interocular parafoveal	188.21 (25.16)	186.23 ( 8.45)	0.708
OD total parafoveal layer	309.03 (16.38)	309.33 (14.40)	0.897
OS total parafoveal layer	303.97 (30.62)	309.59 (14.40)	0.712
Mean macular volume ( $\text{mm}^3$ )			
OD inner parafoveal	0.77 (0.07)	0.76 (0.07)	0.566
OS inner parafoveal	0.76 (0.10)	0.79 (0.06)	0.310
Mean inner interocular	0.77 (0.77)	0.78 (0.06)	0.787
OD outer parafoveal	1.17 (0.06)	1.18 (0.08)	0.617
OS outer parafoveal	1.15 (0.10)	1.14 (0.11)	0.899
Mean outer interocular	1.16 (0.07)	1.16 (0.08)	0.583

P values are based on the Mann-Whitney test.

There was no correlation between the PD patients' age and the inner and outer parafoveal thicknesses and volumes of the right eye, and between the age and the inner and outer parafoveal and perifoveal thicknesses and volumes of the left eye ( $r<-0.20$ ).

A negative correlation was observed between the disease duration and the retinal layer thickness and volume. Extended disease duration was associated with reduced left eye inner parafoveal layer thickness and volume ( $r=-0.35717$ ,  $P=0.0256$ ).

There was a negative correlation between the total UPDRS scores and the total parafoveal thickness ( $r=-0.33281$ ,  $P=0.0383$ ).


There was no correlation between the HY stage and the retinal layer thickness and volume in either eyes ( $r<0.1$ ,  $P>0.05$ ). The RNFL did not correlate with patients' age, PD duration, or the HY stage ( $P>0.05$ ). There was no correlation among the RNFL thickness, VEP latency, patients' age, PD duration, or the HY stage ( $r<-0.20$ ;  $P>0.05$ ).

The mean RNFL thickness correlated positively to the inner perifoveal retinal layer thickness ( $r=0.60302$ ,  $P<0.0001$ ), its volume ( $r=0.59759$ ,  $P<0.0001$ ), and to the total parafoveal layer thickness

**Table 3. Macular perifoveal layer thickness and volume analysis**

	Control	PD	P value
Mean macular thickness ( $\mu\text{m}$ ; SD)			
OD inner perifoveal layer	111.56 ( 8.17)	110.31 ( 7.28)	0.352
OS inner perifoveal layer	110.21 ( 9.78)	111.87 ( 7.17)	0.908
Mean inner interocular perifoveal	110.88 ( 8.08)	111.09 ( 6.82)	0.715
OD outer perifoveal layer	172.90 ( 9.92)	171.74 ( 8.10)	0.799
OS outer perifoveal layer	172.10 ( 9.61)	171.03 ( 7.91)	0.572
Mean outer interocular perifoveal	172.50 ( 8.99)	171.38 ( 7.15)	0.734
OD total perifoveal layer	284.67 (15.37)	282.00 (11.93)	0.352
OE total perifoveal layer	282.44 (17.97)	282.21 (12.80)	0.664
Mean macular volume ( $\text{mm}^3$ )			
OD inner perifoveal	1.40 (0.10)	1.39 (0.09)	0.261
OS inner perifoveal	1.39 (0.12)	1.40 (0.10)	0.976
Mean inner interocular perifoveal	1.39 (0.10)	1.39 (0.09)	0.621
OD outer perifoveal	2.17 (0.13)	2.16 (0.10)	0.810
OS outer perifoveal	2.14 (0.22)	2.09 (0.13)	0.240
Mean outer perifoveal	2.16 (0.15)	2.12 (0.13)	0.353

P values are based on the Mann-Whitney test.



RE= right eye;  $r=-0.42454$ ,  $P=0.007$ .

**Figure 1. Correlation between patients' age and right eye inner perifoveal layer thickness.**

( $r=0.46176$ ,  $P=0.0031$ ). The VEP latencies were not correlated to the inner perifoveal and parafoveal retinal layer thickness or volume ( $r<0.20$ ,  $P>0.05$ ).

The mean interocular outer parafoveal retinal layer thicknesses (SD) were, 183.7 (8.40)  $\mu\text{m}$  in females and 188.21 (8.02)  $\mu\text{m}$  in males ( $P=0.036$ ). The mean interocular outer parafoveal retinal layer volumes (SD) were, 1.15 (0.05)  $\text{mm}^3$  in females vs. 1.17 (0.09)  $\text{mm}^3$  in males ( $P=0.040$ ). The total parafoveal layer thicknesses (SD) were, 302.97 (11.81)  $\mu\text{m}$  in females vs. 313.52 (13.48)  $\mu\text{m}$  in males ( $P=0.017$ ). The VEP P100 latency was lower in female (104.88 ms) than in males (111.13 ms,  $P=0.002$ ) PD patients. In controls, gender-specific differences in VEP or retinal layer thicknesses were not observed.

There was no correlation among the presence of visual symptoms, the mean interocular retinal layer thicknesses and volumes (inner and outer, parafoveal and perifoveal), the RNFL thickness, and the mean P100 VEP latency ( $r<0.20$ ,  $P>0.05$ ).

There was no correlation among the Ishihara scores, the mean interocular retinal layer thickness, its volume, the mean interocular RNFL thickness, and the mean interocular P100 VEP latency ( $r<0.20$ ,  $P>0.05$ ).

### CORRELATIONS WITHIN THE CONTROL GROUP

Older age was positively correlated with increased VEP latencies of the right eye ( $r=0.42543$ ,  $P=0.0108$ ) and the left eye ( $r=0.43343$ ,  $P=0.0093$ ), as well as with increased mean VEP latencies ( $r=0.41969$ ,  $P=0.0121$ ).

Older age negatively correlated with reduced right eye total perifoveal retinal layer thickness ( $r=-0.32861$ ,  $P=0.0440$ ), left eye inner perifoveal layer thickness ( $r=-0.38507$ ,  $P=0.0170$ ), and volume ( $r=-0.39097$ ,  $P=0.0152$ ). Older age correlated negatively with lower mean inner perifoveal thickness ( $r=-0.3483$ ,  $P=0.0318$ ) and volume ( $r=-0.33693$ ,  $P=0.0386$ ).

The mean interocular retinal layer thicknesses and volumes (inner and outer, parafoveal and perifoveal), the mean interocular RNFL thickness, and the mean interocular P100 VEP latency of males and females were similar ( $P>0.05$ ).

The RNFL thickness did not correlated with age ( $r=-0.17161$ ,  $P=0.3029$ ). There was a positive correlation between the RNFL thickness and the mean interocular parafoveal inner layer thickness ( $r=0.39658$ ,  $P=0.0124$ ) as well as between the RNFL thickness and volume ( $r=0.39332$ ,  $P=0.0132$ ). The RNFL thickness positively correlated with the mean interocular inner perifoveal thickness ( $r=0.61725$ ,  $P<0.0001$ ) and volume ( $r=0.63374$ ,  $P<0.0001$ ), the mean interocular outer perifoveal thickness ( $r=0.40547$ ,  $P=0.0104$ ) and volume ( $r=0.41664$ ,  $P=0.0083$ ), and with the mean interocular total perifoveal thickness ( $r=0.5466$ ,  $P=0.0003$ ).

There was no correlation between the RNFL thickness and the VEP latency ( $r=-0.23014$ ,  $P=0.1835$ ).

The complaints regarding vision did not correlate with the mean interocular retinal layer thickness (inner and outer, parafoveal and perifoveal), mean interocular RNFL thickness, and mean interocular P100 VEP latency ( $r<0.20$ ,  $P>0.05$ ).

### DISCUSSION

The impact of PD increases with life expectancy. Difficulty in reading, tiredness of the eyes, diplopia, and blurring of vision are commonly experienced by PD patients<sup>(15)</sup>. Impairments in vision can be due to dysfunctions ranging from that of the extrinsic ocular muscles to that of the occipital visual cortex<sup>(16,17)</sup>. Whereas some deficits likely originate from the central processing tertiary visual areas, other symptoms are related to the alterations in visual acuity and colour, motion, as well as contrast perception. These symptoms have rarely been associated with PD<sup>(16)</sup>. However, one post-mortem study that employed liquid chromatography found reduced dopamine content in the retinas of PD patients<sup>(18)</sup>.

Because PD occurs predominately in population over the age of 50, it was hypothesised that there could be a higher incidence of vision-related complaints in these patients than in controls. However, our results show that visual impairments occurred both in patients (31.58%) and controls (22.22%). Thus, our cohort of PD patients did not emphasise visual complaints other than those secondary to their handicapping motor symptoms<sup>(19)</sup>. Similar to that observed in control group, the most frequently encountered visual symptoms in PD patients were the visual tiredness and blurred vision.

The mean age of this cohort of 43 PD patients was 63.07 years (79.02% between 50 and 69 years), which was similar to that in the control group of 38 individuals (62.39 years). The mean PD duration and HY stage were 6.97 years and 1.78, respectively, which indicated instances of initial to intermediate stages of PD. The total UPDRS mean score (SD) was 17.63 (8.99), indicating a light to moderate severity of PD symptoms.

The results of the Ishihara visual color test were normal for 91.89% of PD patients and 97.37% of controls. These results suggested that the Ishihara visual color test is not appropriate for assessing the colour vision of PD patients. The Farnsworth-Munsell 100 colour test is considered as the best method for evaluating the color perception<sup>(20)</sup>.

The VEP P100 latencies of the PD patients and age-matched controls were similar. We chose the 30' angle check size because it is between the 60' (1 degree, perimacular function test) and the 15' (0.25 degree, foveal function test) check sizes. Because various studies used different VEP stimuli, a comparison of the results is not practical<sup>(6,21,22)</sup>. The VEP latencies did not correlate with the age, PD duration, and the HY stage. However, the VEP latencies and age of subjects in the control group showed an expected positive correlation. Thus, the pattern-shift VEP is a relatively poor method for assessing the anterior visual pathway dysfunction because it is incapable of differentiating impaired macular function from impaired ganglion cell function. However, the pattern electroretinogram would be able to differentiate these processes and assess the status of the retinal ganglion cells<sup>(23)</sup>.

The spectral-domain OCT data did not show any differences in the inner or outer parafoveal and perifoveal retinal layer thicknesses and volume between the PD patients and controls. The PD stage did not correlate with the retinal layer thickness. Our results contradict the results of an earlier spectral-domain OCT study, which found inner retinal macular layer thinning in 24 PD patients<sup>(12)</sup>. Altintas et al., who used time-domain OCT in their study of 17 PD patients (11 controls) found a thinning of the inner superior, outer inferior temporal, and nasal macular regions, as well as a lower mean macular volume and an inverse correlation between the foveal thickness and motor handicap<sup>(11)</sup>. Albrecht et al. found a thicker inner nuclear layer in 40 PD patients. Factors, such as the different methods used for measuring the retinal layers and measuring only at their thickest sections, may have contributed to these differences<sup>(24)</sup>. The relatively smaller sample size used in earlier studies may also have contributed to the differences in the results of OCT<sup>(12,16)</sup>.

Our results are similar to that of Archibald et al., who found no differences between the macular thicknesses of 32 PD patients and 19 controls<sup>(16)</sup>. Schneider et al used a newly developed semiautomatic algorithm for spectral domain OCT. This algorithm enabled a retinal single-layer analysis and calculation of the average thickness of retinal layers in Parkinsonian syndromes. The authors calculated the average thickness of single retinal layers to foveal scans of 65 PD patients, 16 progressive supranuclear palsy (PSP) patients, 12 patients with multiple system atrophy (MSA), and 41 matched controls. Compared with controls, a significant reduction in the thickness of retinal layers was found only in PSP and MSA patients. The single retinal layer measurement of the PD patients revealed no significant changes. Notably, the thickening of the outer nuclear layer in PSP and that of the outer plexiform layer in MSA was highly specific to these diseases and helped distinguish PSP from MSA with high sensitivity and specificity<sup>(25)</sup>.



The thickness of the RNFL of the PD patients was similar to that of the control subjects. Previous reports of OCT studies described a thinner RNFL in PD patients<sup>(10,11,13)</sup>. However, Archibald et al. who employed time-domain OCT found no such thinning of the RNFL in PD patients<sup>(16)</sup>. The RNFL thickness did not correlate with patient's age, PD disease duration, and HY stage. Similar to that found in the control group, a positive correlation between the retinal layer thickness, volume, and RNFL thickness was observed. However, further studies are needed to verify the validity of these results.

The effect of aging on retinal layer thickness was seen in both PD and controls, suggesting that the retinal thinning was age-related and cannot be considered as a biomarker of this disease. The male PD patients showed higher retinal layer thickness and volume than the female patients. Such gender differences were not observed in control group. A predominance of the initial stages of the disease was seen in the PD group. The HY stage did not correlate with the retinal layer thickness and volume. There were no correlations between VEP latencies and the retinal layer thickness and volume.

In PD patients, gender differences in the mean outer interocular parafoveal and total thickness and the mean outer interocular parafoveal volume were observed. These values were lower in females. However, such gender differences were not observed in the control group.

In both PD patients and controls, there was no correlation between complaints regarding vision, mean interocular retinal layer and mean RNFL thicknesses, retinal layer volumes, and the mean VEP latencies.

During this study, we encountered technical problems such as tremor interferences in OCT and VEP analyses. Therefore, we excluded those patients who could not tolerate the examinations and registers that did not have technical requirements for the analysis. Despite these technical difficulties, our study included a considerable number of subjects because our inclusion/exclusion criteria were rigorous and excluded ocular and systemic pathologies.

## REFERENCES

- Lang AE, Lozano AM. Parkinson's disease: first of two parts. *N Engl J Med*. 1998; 339(15):1044-53.
- Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). *J Neurol*. 2002;249 Suppl 3:III/1-5.
- Bodis-Wollner I, Yahr M. Measurements of visual evoked potentials in Parkinson's disease. *Brain* 1978;101(4):661-71.
- Regan D, Neima D. Low-contrast letter charts in early diabetic retinopathy, ocular hypertension, glaucoma and Parkinson's disease. *Br J Ophthalmol*. 1984;68(12):885-9.
- Onofrij M, Ghilardi MF, Basciani M, Gambi D. Visual evoked potentials in Parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. *J Neurol Neurosurg Psychiatry*. 1986;49(10):1150-9.
- Mariani AP. Amacrine cells of the rhesus monkey retina. *J Comp Neurol*. 1990;301(3):382-400.
- Kolb H, Cuenca N, Wang HH, Dekorver L. The synaptic organization of the dopaminergic amacrine cell in the cat retina. *J Neurocytol*. 1990;19(3):343-66.
- Witkovsky P, Nicholson C, Rice ME, Bohmaker K, Meller E. Extracellular dopamine concentration in the retina of the clawed frog, *Xenopus laevis*. *Proc Natl Acad Sci USA*. 1993;90(12):5667-71.
- Bodis-Wollner I, Antal A. Optic nerve and central nervous dysfunctions: Parkinson's disease and multiple sclerosis. In: Heckenlively JR, Arden GB, editors. *Principles and practice of clinical electrophysiology of vision 2<sup>nd</sup> ed*. Cambridge, Massachusetts, London, England: The MIT Press; 2006. p.867-88.
- Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. *Vision Res*. 2004;44(24):2793-7.
- Altintas O, Iseri P, Ozkan B, Caglar Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease. *Doc Ophthalmol*. 2008; 116(2):137-46.
- Hajee ME, March WF, Lazzaro DR, Wolintz AH, Shrier EM, Glazman S, et al. Inner retinal layer thinning in Parkinson disease. *Arch Ophthalmol*. 2009;127(6):737-41.
- Moschos MM, Tagaris G, Markopoulos I, Margetis I, Tsapakis S, et al. Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. *Eur J Ophthalmol*. 2011;21(1):24-9.
- Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. *J Neural Transm Suppl*. 1993;39:165-72.
- Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. *Brain*. 2000;123(Pt 4):733-45.
- Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Retinal thickness in Parkinson's disease. *Parkinsonism Relat Disord*. 2011;17(6):431-6.
- Almer Z, Klein KS, Marsh L, Gerstenhaber M, Repka MX. Ocular motor and sensory function in Parkinson's disease. *Ophthalmology*. 2012;119(1):178-82.
- Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. *Invest Ophthalmol Vis Sci*. 1990;31(11):2473-5.
- Bodis-Wollner I, Antal A. Primary visual and visuocognitive deficits. In: Pfeiffer RF, Bodis-Wollner I, editors. *Parkinson's disease and nonmotor dysfunction*. Totowa, NJ: Humana Press; 2005. cap 20. p.233-44.
- Marras C, Schuele B, Munhoz RP, Rogaeva E, Langston JW, Kasten M, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. *Neurology*. 2011;77(4):325-33.
- Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. *Trends Neurosci*. 1990;13(7):296-302.
- Masson G, Mestre D, Blin O. Dopaminergic modulation of visual sensitivity in man. *Fundam Clin Pharmacol*. 1993;7(8):449-63.
- Sartucci F, Orlandi G, Lucetti C, Bonuccelli U, Murri L, et al. Visuo-cognitive dysfunctions in Parkinson's disease. *J Clin Neurophysiol*. 2003;20(5):375-81.
- Albrecht P, Muller A K, Sudmeyer M, Ferrea S, Ringelstein M, et al. Optical coherence tomography in parkinsonian syndromes. *PLOS One*. 2012;7(4):e34891.
- Schneider M, Muller HP, Lauda F, Tumani H, Ludolph AC, Kassubeck J, et al. Retinal single-layer analysis in Parkinsonian syndromes: an optical coherence tomography study. *J Neural Transm*. 2014;121(1):41-7.